Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment

NCT ID: NCT06851975

Last Updated: 2025-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-07

Study Completion Date

2099-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research into biomarkers predictive of survival and response to cancer treatment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

principal

blood sampling

Group Type OTHER

blood sampling

Intervention Type OTHER

36ml of blood will be taken during a blood sampling performed in standard practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sampling

36ml of blood will be taken during a blood sampling performed in standard practice

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient having a blood test, venous line insertion or injection on an implantable venous device scheduled as part of their standard care,
* Patient who has read the information note and stated that he/she has no objections
* Patient who has not objected to the use of this data for medical research purposes
* Patient with social security cover.

Exclusion Criteria

* Patient already included in the study
* Patient considered to be a vulnerable person; vulnerable persons are defined in article L1121-5 to -8
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Antoine Lacassagne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Antoine Lacassagne

Nice, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Victoria FERRARI, Dr

Role: CONTACT

+33 492031311

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Victoria FERRARI

Role: primary

+33492031311

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-61

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tumor-Derived FGF19
NCT06068257 RECRUITING